Our Pricing

Mounjaro vs Saxenda: Clinical Comparison for UK Patients

When evaluating mounjaro vs saxenda uk comparison options, understanding the clinical differences between tirzepatide and liraglutide is essential for making an informed choice. Both injectable medications are licensed by the MHRA for weight management in the UK, but they work through different mechanisms and produce distinct results in clinical trials. At Cured Pharmacy, our UK-registered prescribers assess your individual health profile to determine which treatment may be most suitable, with both medications available following a free online consultation.

How Mounjaro and Saxenda Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK for weight management [1]. This dual-action mechanism activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, insulin secretion, and energy expenditure compared to single-pathway treatments.

Saxenda contains liraglutide, a GLP-1 receptor agonist that has been available in the UK since 2015 [2]. Liraglutide works by mimicking the natural GLP-1 hormone, which slows gastric emptying, reduces appetite, and improves glycaemic control. While effective, it activates only one metabolic pathway rather than the dual mechanism seen with tirzepatide.

The key pharmacological distinction lies in tirzepatide's additional GIP receptor activation, which appears to amplify weight loss effects beyond what GLP-1 agonism alone can achieve [1]. This difference translates into measurably different outcomes in head-to-head clinical comparisons.

Clinical Trial Results: Mounjaro vs Saxenda Effectiveness

In the SURMOUNT-1 trial, patients taking the highest Mounjaro dose (15mg weekly) achieved an average body weight reduction of 22.5% over 72 weeks, with 91% of participants losing at least 5% of their initial weight [1]. These results represent some of the highest weight loss outcomes observed in obesity medication trials to date.

The SCALE Obesity and Prediabetes trial, which evaluated Saxenda, showed an average weight loss of 8.4kg (approximately 8% body weight) over 56 weeks, with 63.2% of participants achieving at least 5% weight reduction [2]. While clinically significant, these results demonstrate a notable difference in magnitude compared to tirzepatide outcomes.

It's important to note that individual responses vary considerably, and clinical trial averages don't predict any single patient's outcome. Your UK prescriber will consider your medical history, weight loss goals, and tolerance for potential side effects when recommending between these treatments.

Weight Loss Trajectory and Timeline

Mounjaro typically produces gradual weight loss that accelerates as the dose is titrated upward over 20-24 weeks to the maintenance level [1]. Patients often notice appetite suppression within the first few weeks, with measurable weight changes becoming apparent by week 4-8.

Saxenda requires daily injections with a shorter titration period of 5 weeks to reach the maintenance dose of 3mg [2]. Weight loss tends to be more linear, with steady reductions observed throughout the treatment period when combined with dietary modifications and increased physical activity.

Dosing and Administration: Mounjaro vs Saxenda UK

Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled KwikPen. The standard titration schedule begins at 2.5mg weekly for 4 weeks, increasing to 5mg, then 7.5mg, 10mg, 12.5mg, and potentially 15mg depending on individual response and tolerability [3]. This gradual escalation helps minimise gastrointestinal side effects whilst optimising efficacy.

Saxenda requires daily subcutaneous injections, starting at 0.6mg and increasing by 0.6mg increments each week until reaching the maintenance dose of 3mg daily [2]. The multi-dose pen must be stored in the refrigerator and replaced every 30 days once in use, regardless of remaining medication.

The once-weekly dosing of Mounjaro offers a practical advantage for patients who prefer fewer injections, whilst Saxenda's daily administration provides more consistent medication levels throughout each 24-hour period. Both medications are injected subcutaneously in the abdomen, thigh, or upper arm.

Side Effects Profile: What UK Patients Experience

Both medications share similar gastrointestinal side effects due to their GLP-1 receptor activity. The most commonly reported adverse events include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][2]. These effects are typically most pronounced during dose escalation and tend to diminish over time as the body adapts.

In clinical trials, nausea occurred in approximately 44% of Mounjaro patients at the highest dose, compared to 39% of Saxenda patients [1][2]. However, discontinuation rates due to gastrointestinal side effects were comparable between the two treatments, suggesting similar overall tolerability despite the higher weight loss observed with tirzepatide.

Rare but serious potential side effects for both medications include pancreatitis, gallbladder disease, and hypoglycaemia (particularly when used alongside other glucose-lowering medications). Your UK prescriber will review your medical history for contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Managing Side Effects During Treatment

Most patients find that gastrointestinal symptoms can be minimised by eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated. The gradual dose titration schedule for both medications is specifically designed to improve tolerability.

If side effects become troublesome, your prescriber may recommend remaining at your current dose for an additional week or two before increasing, or in some cases, reducing to the previous dose level. Never adjust your dose without consulting your UK prescriber first.

Mounjaro vs Saxenda: Cost and Availability in the UK

At Cured Pharmacy, Mounjaro is available from £135.00 following approval by a UK prescriber, whilst Saxenda starts from a lower entry price point. Both medications require a prescription and cannot be purchased over the counter in the UK, as they are classified as prescription-only medicines (POM) by the MHRA.

The cost difference reflects several factors, including the newer patent status of tirzepatide, the once-weekly versus daily dosing frequency, and the different manufacturing processes. When comparing overall treatment costs, it's important to consider the dose escalation schedule and maintenance dose requirements for your individual treatment plan.

Both medications are currently in stock at Cured Pharmacy, following previous UK-wide supply constraints that affected multiple weight management treatments throughout 2023 and early 2024. Our transparent pricing model shows you the exact cost before you complete your clinical assessment, with no hidden consultation fees or subscription requirements.

Which Treatment Is Right for You: Clinical Considerations

Choosing between Mounjaro and Saxenda depends on multiple individual factors beyond just comparative efficacy data. Your UK prescriber will consider your BMI, weight loss goals, previous treatment responses, medical history, current medications, and lifestyle factors including your ability to adhere to daily versus weekly injections.

Mounjaro may be particularly suitable for patients seeking maximum weight loss potential who can tolerate the longer titration period and once-weekly injection schedule [1]. Saxenda may be preferred for patients who have previously responded well to GLP-1 agonists, those who prefer more frequent dosing for consistent medication levels, or those for whom cost considerations are paramount [2].

Both treatments work most effectively when combined with a reduced-calorie diet and increased physical activity, as demonstrated in their respective clinical trials [1][2]. Neither medication is a standalone solution, and sustainable weight management requires ongoing lifestyle modifications alongside pharmacological support. Your prescriber will discuss realistic expectations and the importance of comprehensive weight management strategies during your consultation.

Starting Your Treatment Journey

At Cured Pharmacy, the process begins with a free online consultation that takes under 3 minutes to complete. Our UK-registered prescribers review your medical history, current health status, and weight management goals to determine whether Mounjaro, Saxenda, or an alternative treatment is most appropriate for your individual circumstances.

Once approved, your medication is dispensed by our UK-registered pharmacy (GPhC 9012511) and delivered in discreet packaging directly to your address. Our clinical team remains available throughout your treatment for dose adjustments, side effect management, and ongoing support as you progress towards your weight loss goals.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.